View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 18, 2021updated 12 Jul 2022 11:21am

Hovione completes trial of Meizuvo for dry eye disease caused by MGD

Hovione has completed the Phase II trial of Meizuvo, a minocycline repurposed for ophthalmic administration, for dry eye disease caused by Meibomian Gland Dysfunction (MGD).

Hovione has completed the Phase II trial of Meizuvo, a minocycline repurposed for ophthalmic administration, for dry eye disease caused by Meibomian Gland Dysfunction (MGD).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The well controlled and representative study was conducted across 26 clinical sites in the US and included 270 subjects suffering from dry eye associated with MGD.

It tested two different strengths of minocycline against vehicle in a 1:1:1 randomisation.

According to the company, the study observed a favourable clinical outcome in 70% of subjects with positive inflammatory biomarker at baseline.

Following two weeks of treatment, these patients achieved statistically significant improvement of 25 points in the Visual Analogue Scale (VAS) discomfort.

The figure subsequently increased to 35 points by the end of treatment, representing an improvement of more than 50%.

Less than 3% of subjects reported blurring vision or eye irritation, indicating that the product is safe and well tolerated.

Hovione innovative proprietary portfolio vice-president Carla Vozone said: “The correlation between the patients with a positive [matrix metalloproteinase] MMP-9 assay at baseline and the clinical improvement observed in both signs and symptoms of dry-eye was groundbreaking.”

MGD is an eye condition where the eyelid glands alter the lipid composition of the tears and triggers evaporation-induced tear hyperosmolarity.

In the US, around 27 million people suffer from evaporative dry eye, which is largely caused by MGD.

Hovione offers services for drug substance, drug product intermediate and drug product. The company has manufacturing plants in the US, Portugal, Macau and Ireland.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena